Diabetes and metabolic syndrome

Abstract

Catheter-based renal denervation (RDN) reduces sympathetic nerve activity and blood pressure in patients with resistant hypertension [1-3]. Increased central sympathetic activity is a main contributor to the pathophysiology of several important chronic cardiovascular diseases, including diabetes and the metabolic syndrome. A body of preclinical and clinical evidence indicates the profound relationship between sympathetic overactivity and metabolic disorders. Indeed several recently published pilot studies and case reports suggest beneficial effects of RDN on glucose metabolism in patients with resistant hypertension.